Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 01/17/17 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
7 | |
| 01/17/17 | 8-K | Current report filing |
|
7 | |
| 01/13/17 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
5 | |
| 01/13/17 | 8-K | Current report filing |
|
4 | |
| 01/04/17 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses |
|
16 | |
| 01/03/17 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses |
|
3 | |
| 01/03/17 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 12/30/16 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 12/30/16 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
11 | |
| 12/30/16 | 8-K | Current report filing |
|
12 |
